ALP Life Sciences, LLC, Applied Lipid Polymorphism ALP Life Sciences, LLC, founded in 2008, is a life sciences research and development company targeting liver diseases. The Company is focused on therapeutics, diagnostics and drug metabolism testing utilizing the emerging science of Applied Lipid Polymorphism. Nanoveson™ is the first therapy pursued for commercialization by the Company, utilizing only natural compounds. The current research on the proposed mechanisms of action of Nanoveson™ and details of the biochemistry cascade it produces are presented in the Nanoveson™ whitepaper. Treatment for non-alcoholic fatty liver diseases (NAFLD), is the first indication target, but Nanoveson™ also has the potential to treat other liver diseases and multiple related diseases. Nanoveson™ has potential to generate biomarkers for diagnostic tests for NAFLD and other liver diseases and related diseases. Nanoveson™ potentially offers a new and effective approach to drug metabolism testing, for which there is a significant commercial need. Nanoveson™ triggers the polymorphism of triglyceride stores in the liver into phospholipids in bile. By increasing phospholipid concentration and dropping pH in the intestines, the therapy triggers the fusion and aggregation of lipid membranes, micelles and vesicles in the intestines, and their aggregation into large lipid structures for elimination. The Nanoveson™ therapy mechanisms of action may treat inflammatory diseases, including asthma, arthritis, cardiovascular diseases, gastrointestinal diseases, diabetes and cancer by targeting and improving enterohepatic circulation, which is how the body maintains whole body quantitative homeostasis of arachidonic acid. Arachidonic acid metabolism is implicated in many inflammatory diseases along multiple pathways. Orphan disease indication targets may be pursed through clinical trials focused on arachidonic acid specific surrogate end points. Alplifesciences.com~Site InfoWhoisTrace RouteRBL Check
